Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Sold by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 19.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 67,367 shares of the company’s stock after selling 16,306 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.14% of Amphastar Pharmaceuticals worth $2,501,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Smartleaf Asset Management LLC raised its position in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after acquiring an additional 493 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in Amphastar Pharmaceuticals by 806.5% during the 4th quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after buying an additional 871 shares during the period. Point72 Asia Singapore Pte. Ltd. increased its position in shares of Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after acquiring an additional 398 shares in the last quarter. KBC Group NV raised its holdings in shares of Amphastar Pharmaceuticals by 43.1% during the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock valued at $80,000 after acquiring an additional 650 shares during the period. Finally, PNC Financial Services Group Inc. lifted its position in shares of Amphastar Pharmaceuticals by 90.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock valued at $156,000 after acquiring an additional 1,992 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on AMPH. Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Piper Sandler lowered Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price target for the company from $66.00 to $36.00 in a research report on Tuesday, February 4th.

Insider Buying and Selling

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the transaction, the chief financial officer now owns 97,363 shares in the company, valued at $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Trading Down 1.2 %

NASDAQ AMPH opened at $27.36 on Wednesday. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals, Inc. has a 1-year low of $25.89 and a 1-year high of $53.96. The firm’s fifty day simple moving average is $32.42 and its 200-day simple moving average is $40.89. The company has a market capitalization of $1.30 billion, a PE ratio of 9.12, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.